Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma.
Jessica Rodrigues PlaçaArjan DiepstraG Tjitske Los-de VriesMatías MendevilleAnnika SeitzPieternella J LugtenburgJosée J M Zijlstra-BaalbergenKing LamWilson Araújo da Silva JuniorBauke YlstraDaphne de JongAnke van den BergMarcel NijlandPublished in: Cancers (2022)
Multiple gene expression profiles have been identified in diffuse large B-cell lymphoma (DLBCL). Besides the cell of origin (COO) classifier, no signatures have been reproduced in independent studies or evaluated for capturing distinct aspects of DLBCL biology. We reproduced 4 signatures in 175 samples of the HOVON-84 trial on a panel of 117 genes using the NanoString platform. The four gene signatures capture the COO, MYC activity, B-cell receptor signaling, oxidative phosphorylation, and immune response. Performance of our classification algorithms were confirmed in the original datasets. We were able to validate three of the four GEP signatures. The COO algorithm resulted in 94 (54%) germinal center B-cell (GCB) type, 58 (33%) activated B-cell (ABC) type, and 23 (13%) unclassified cases. The MYC-classifier revealed 77 cases with a high MYC-activity score (44%) and this MYC-high signature was observed more frequently in ABC as compared to GCB DLBCL (68% vs. 32%, p < 0.00001). The host response (HR) signature of the consensus clustering was present in 55 (31%) patients, while the B-cell receptor signaling, and oxidative phosphorylation clusters could not be reproduced. The overlap of COO, consensus cluster and MYC activity score differentiated six gene expression clusters: GCB/MYC-high (12%), GCB/HR (16%), GCB/non-HR (27%), COO-Unclassified (13%), ABC/MYC-high (25%), and ABC/MYC-low (7%). In conclusion, the three validated signatures identify distinct subgroups based on different aspects of DLBCL biology, emphasizing that each classifier captures distinct molecular profiles.
Keyphrases
- diffuse large b cell lymphoma
- gene expression
- genome wide
- transcription factor
- epstein barr virus
- dna methylation
- immune response
- machine learning
- deep learning
- single cell
- newly diagnosed
- clinical trial
- stem cells
- ejection fraction
- toll like receptor
- genome wide identification
- protein kinase
- randomized controlled trial
- rna seq
- inflammatory response
- mesenchymal stem cells
- bone marrow
- phase ii
- case control